AUS
NZ
UK
CA
USA
IND
Highlights
- Genus (GNS) shares rose by 1.1% on Wednesday.
- Shore Capital upgraded Genus to a rating.
- Insider Jorgen Kokke sold 2,186 shares at an average price of GBX 1,956.
Genus plc (LON:GNS), a leader in animal genetics, saw its stock rise by 1.1% on Wednesday, opening at GBX 1,660. The increase followed a period of relative stability, with the stock showing notable fluctuations over the past 52 weeks, trading between a low of GBX 1,478 and a high of GBX 2,378. The company boasts a market capitalization of £1.09 billion, reflecting its significant presence in the animal genetics industry. Despite the modest price movement, Genus continues to maintain a solid financial footing with a P/E ratio of 13,833.33, a P/E/G ratio of 2.87, and a low beta of 0.37, suggesting stable performance in comparison to broader market trends. As part of the broader LON healthcare stocks landscape, Genus contributes to advancements in animal breeding and genetics, which play a crucial role in healthcare, particularly in improving food production and addressing global health challenges.
In terms of financial health, Genus demonstrates strong liquidity with a quick ratio of 1.08 and a current ratio of 1.80, indicating its ability to meet short-term obligations. The company also has a debt-to-equity ratio of 53.54, suggesting a balanced approach to leveraging its capital. Its 50-day moving average of GBX 1,907.74 and 200-day moving average of GBX 1,822.87 point to a steady price trend in recent months.
Despite the positive stock performance, insider transactions have raised some attention. On September 16th, Jorgen Kokke, a company insider, sold 2,186 shares of the company's stock at an average price of GBX 1,956. This sale represented a minor 0.75% of the company’s stock being offloaded by insiders, but it is still a point of interest for those following the company’s movements.
Genus operates as an animal genetics company with a global reach, operating in regions including North America, Latin America, Europe, the Middle East, and Asia. The company is divided into three main segments: Genus PIC, Genus ABS, and Genus Research and Development. It specializes in the breeding of pigs and the sale of semen under its PIC brand, providing genetically enhanced livestock to support pork production. As the company continues to expand its genetic research and development, it is poised to maintain its position as a leader in the animal genetics market.
